Analyst Ratings for Fennec Pharmaceuticals
Portfolio Pulse from Benzinga Insights
Analysts have provided bullish ratings for Fennec Pharmaceuticals (NASDAQ:FENC) in the last quarter, with an average 12-month price target of $17.5, up 45.83% from the previous average of $12.00.
June 21, 2023 | 2:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Fennec Pharmaceuticals has received bullish ratings from analysts, with an average 12-month price target of $17.5, up 45.83% from the previous average of $12.00.
The bullish ratings from analysts indicate a positive outlook for Fennec Pharmaceuticals. The average 12-month price target has increased by 45.83% from the previous average, suggesting that analysts believe the stock has potential for growth in the short term. This could lead to an increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100